Cipla shares jump 10% after USFDA paves the way for an important drug launch

Out of the 38 analysts that have coverage on Cipla, 21 of them have a “buy” rating on the stock, eight of them said “hold”, while nine of them have a “sell” rating on the stock.

Leave a Reply

Your email address will not be published. Required fields are marked *